论文部分内容阅读
冠心病是目前人类健康面临的重大挑战。人们已经认识到,在众多冠心病危险因素中,胆固醇是最重要的致病性因素,降低胆固醇业已成为现代冠心病防治的重要方面。随着循证医学的不断发展,调脂治疗的理论也在不断深入发展和演变之中。降低胆固醇是调脂治疗的主旋律,而近年来强化降脂理论的提出进一步推动了调脂治疗的发展。顾名思义,强化降脂需要更大力度地降低脂质,即相对于一般降脂而言,更为积极地降脂治疗,强调达到目标值或更低。强化降脂的标准可简单概括为三个指标(两个目标值,一个幅度):降低低密度脂蛋白胆固醇(LDL-C)至<100mg/dl、<70mg/dl或降低幅度>30%-40%。对于他汀类降脂,日益积累的证据表明:早期使用,早期获;长期使用。长期获益,强化降脂,更大获益。
Coronary heart disease is currently a major challenge to human health. It has been recognized that many of the risk factors for coronary heart disease, cholesterol is the most important pathogenic factors, lower cholesterol has become an important aspect of modern prevention and treatment of coronary heart disease. With the continuous development of evidence-based medicine, the theory of lipid-lowering treatment is also constantly evolving and evolving. Cholesterol lowering is the main theme of lipid-lowering therapy, and in recent years to strengthen the lipid-lowering theory put forward to further promote the development of lipid-lowering therapy. As the name implies, intensifying lipid-lowering requires more intensive lipid lowering, ie more aggressive lipid-lowering treatment relative to normal lipid lowering, with emphasis on reaching target values or lower. The criteria for enhancing lipid-lowering can be briefly summarized as three indicators (two target values, one amplitude): lower LDL-C to <100 mg / dl, <70 mg / dl, or a decrease of> 30% 40%. For statin lipid-lowering, increasing evidence accumulates that early use, early use, long-term use. Long-term benefit, strengthen lipid-lowering, greater benefit.